bexobrutideg

News

Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.

News

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.